What Eagle Materials (EXP)'s Record Revenue and Declining Net Income Reveal About Its Investment Story

• Eagle Materials Inc. reported mixed second quarter results in late October 2025, with record revenue of US$638.91 million driven by cement and aggregates, but net income fell year-on-year as wallboard volumes declined due to softer residential construction activity.
• The company continued its significant share buyback initiative and advanced modernization projects at its cement and wallboard plants, aiming to enhance production efficiency and lower costs amid current sector headwinds.
• We'll now assess how the combination of record revenue and declining net income informs Eagle Materials' investment narrative going forward.

AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Eagle Materials Investment Narrative Recap

To be a shareholder in Eagle Materials, you need confidence that federal and state infrastructure spending can drive steady cement and aggregates growth, offsetting cyclical downturns in residential construction and wallboard demand. The latest results, record revenue despite declining net income, do not materially alter this immediate outlook; infrastructure momentum remains the key catalyst, while continued weakness in residential construction is the biggest risk and remains unchanged in significance.

Among recent company announcements, the progress on major modernization and expansion projects at the Laramie, Wyoming cement plant and Duke, Oklahoma wallboard facility stands out. This commitment to operational efficiency directly targets the company’s ability to lower costs and mitigate earnings risk, which is particularly relevant now as pressures in residential-related products increase.

However, investors should also be aware that despite solid revenue trends, there are ongoing concerns about...

Read the full narrative on Eagle Materials (it's free!)

Eagle Materials is forecast to reach $2.6 billion in revenue and $524.5 million in earnings by 2028. This outlook assumes a 3.8% annual revenue growth rate and a $71.6 million increase in earnings from the current $452.9 million level.

Uncover how Eagle Materials' forecasts yield a $251.70 fair value, a 22% upside to its current price.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community range from US$129.50 to US$448.90 per share, reflecting wide differences in expected future performance. Such dispersion highlights uncertainties, particularly given ongoing headwinds in residential construction that continue to weigh on profitability.

Explore 4 other fair value estimates on Eagle Materials - why the stock might be worth 37% less than the current price!

Build Your Own Eagle Materials Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Eagle Materials research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Eagle Materials research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Eagle Materials' overall financial health at a glance.

Searching For A Fresh Perspective?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• We've found 17 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com